GlassScriptPhysician profile
Amber Hatley
NPI 1770161416
$1,323.11
in general payments reported to CMS, 2019-2025
22 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $214 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $227.21 | 2024-2025 | |
| Novo Nordisk INC | $173.74 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $139.98 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.08 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $107.54 | 2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $74.77 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $62.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $62.47 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $58.59 | 2024-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $38.38 | 2025 | |
| Azurity Pharmaceuticals, INC. | $30.32 | 2024-2025 | Horizant |
| Dexcom, INC. | $29.41 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $27.82 | 2025 | Trelegy Ellipta |
| Vertex Pharmaceuticals Incorporated | $26.84 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.27 | 2025 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.04 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $18.92 | 2025 | Voquezna |
| Ars Pharmaceuticals Operations, INC. | $18.80 | 2025 | Neffy |
| Nevro Corp. | $17.55 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.54 | 2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $14.46 | 2025 | Qelbree |
| Antares Pharma, INC. | $13.46 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Hatley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.